Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Zymeworks Inc (ZYME)

Zymeworks Inc (ZYME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
InMed Pharmaceuticals (NASDAQ: INM) Names New Chief Financial Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has announced the appointment of Netta Jagpal,...

INM : 0.2624 (-0.87%)
QBTS : 0.9800 (-3.92%)
ZYME : 9.71 (-0.72%)
Zymeworks to Join NASDAQ Biotech Index

Zymeworks Inc. (NASDAQ: ZYME) gained ground Friday, as the clinical-stage biotechnology company developing ...

ZYME : 9.71 (-0.72%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 22, 2023 – USA News Group  –  Despite the potential federal funding challenges due to the recent debt ceiling...

RY : 111.45 (+0.29%)
RY.TO : 153.15 (+0.33%)
ONCY : 1.0200 (-0.97%)
ONC.TO : 1.42 (+0.71%)
JAZZ : 107.56 (-1.33%)
ZYME : 9.71 (-0.72%)
AMGN : 334.43 (+0.95%)
PTGX : 35.74 (+0.53%)
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty

/PRNewswire/ -- USA News Group - Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer...

ONC.TO : 1.42 (+0.71%)
ONCY : 1.0200 (-0.97%)
ZYME : 9.71 (-0.72%)
JAZZ : 107.56 (-1.33%)
PTGX : 35.74 (+0.53%)
AMGN : 334.43 (+0.95%)
Pioneering Cancer Treatments Show Promising Progress Despite Fiscal Challenges

USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal, optimism in the battle against cancer persists, thanks in large part to the audacious “Cancer...

RY : 111.45 (+0.29%)
RY.TO : 153.15 (+0.33%)
ONCY : 1.0200 (-0.97%)
ONC.TO : 1.42 (+0.71%)
JAZZ : 107.56 (-1.33%)
ZYME : 9.71 (-0.72%)
AMGN : 334.43 (+0.95%)
PTGX : 35.74 (+0.53%)
2 Biotech Stocks That Could Make You Richer

These biotech companies are seeing a spike in revenue growth.

VYGR : 8.37 (-0.26%)
ZYME : 9.71 (-0.72%)
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meaningful clinical benefit including antitumor activity,...

JAZZ : 107.56 (-1.33%)
ZYME : 9.71 (-0.72%)
Zymeworks To Host First Quarter 2023 Results Conference Call

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will report its first quarter 2023 financial results...

ZYME : 9.71 (-0.72%)
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the appointment of Derek J. Miller to its board of directors effective...

ZYME : 9.71 (-0.72%)
Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor...

ZYME : 9.71 (-0.72%)

Barchart Exclusives

Up 121% Since May, What's Behind the Surge in this Penny Stock?
BuzzFeed is a beaten-down tech stock that has gained traction in recent months as several high-profile investors have taken a stake in the media company. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar